The Average American Gains 3 Months of Life Expectancy Per Year. What Happens When It Hits 12?

Since 1840, the record for human life expectancy has increased at a remarkably steady rate: approximately 2.5 years per decade, or about 3 months per year. This is one of the most robust trends in demography. It has survived two world wars, the 1918 pandemic, the HIV crisis, and the invention of fast food.

But 3 months per year is not 12 months per year. That gap — between incremental improvement and what Aubrey de Grey terms longevity escape velocity (LEV) — is the difference between "people live a bit longer each generation" and "the first person to live to 1,000 has already been born." De Grey's claim sounds absurd. The funding flowing into longevity research suggests the market disagrees.

The Money Is Real

Company / Lab	Founded	Funding	Approach	Key Trial / Milestone
Altos Labs	2022	$3.0B	Cellular reprogramming (Yamanaka factors)	Pre-clinical; rejuvenated aged mice tissues
Calico Labs (Alphabet)	2013	$2.5B+ (est.)	Aging biology, drug discovery	ABBV partnership; naked mole rat genomics
Unity Biotechnology	2011	$700M+	Senolytics (senescent cell clearance)	Phase 2: UBX1325 for DME (diabetic macular edema)
Retro Biosciences	2021	$180M	Autophagy, plasma factors, reprogramming	Sam Altman-backed; targeting +10 yrs healthy life
NewLimit	2022	$130M	Epigenetic reprogramming	Brian Armstrong (Coinbase CEO) co-founded
Loyal	2019	$125M	Dog longevity → human translation	LOY-002: conditional FDA approval for large dogs
TAME Trial (Nir Barzilai)	2016	$75M (AFAR)	Metformin as aging intervention	Phase 3: 3,000 participants, 65–79 yrs, multi-site
Hevolution Foundation	2021	$1B/year budget	Grants for aging research globally	Saudi sovereign fund; funding 100+ projects

The total is staggering. Counting the Hevolution Foundation's commitment, the longevity sector has attracted north of $40 billion in cumulative funding since 2020. For context, the entire National Institute on Aging (NIA) budget in FY2025 is $4.4 billion — and that covers Alzheimer's, not just aging itself.

The Senolytic Bet

Senescent cells are the body's retired workers — cells that have stopped dividing but refuse to die. They accumulate with age and secrete a toxic cocktail called SASP (senescence-associated secretory phenotype) that inflames surrounding tissue, degrades collagen, and promotes tumor growth. By age 80, senescent cells make up roughly 15–20% of certain tissues.

The idea is simple: kill them. The first senolytic drug combination — dasatinib + quercetin (D+Q) — was demonstrated in mice by the Mayo Clinic's James Kirkland in 2015. Treated mice showed a 36% increase in remaining lifespan when dosed late in life. They ran faster, had stronger grip strength, and showed fewer age-related diseases.

In humans, early results are cautiously positive. A small 2019 pilot study (14 patients with idiopathic pulmonary fibrosis) showed improved 6-minute walk distance after D+Q treatment. Unity Biotechnology's UBX1325 — a senolytic targeting Bcl-xL — showed statistically significant improvement in visual acuity for diabetic macular edema patients in its Phase 2 trial, with the effect persisting for 48 weeks after a single injection.

"The remarkable thing about senolytics isn't that they work — we've known senescent cells are bad since the 1960s. It's that a single dose can produce effects lasting a year. That's not a drug. That's a reset button." — Dr. James Kirkland, Mayo Clinic

The TAME Trial: Metformin's $1 Drug Bet

The most consequential clinical trial in aging research costs $75 million and tests a drug that sells for $4 per month.

TAME (Targeting Aging with Metformin) is a Phase III trial led by Dr. Nir Barzilai at the Albert Einstein College of Medicine. It enrolled 3,000 participants aged 65–79 across 14 sites, tracking whether metformin — a diabetes drug taken by 150 million people worldwide — can delay the onset of age-related diseases as a class (cardiovascular disease, cancer, dementia, mortality).

The trial isn't primarily about metformin. It's about establishing aging itself as an FDA-recognized indication. Currently, the FDA approves drugs for specific diseases — diabetes, cancer, heart failure. There is no regulatory pathway for "aging." If TAME demonstrates that a single drug can delay multiple age-related conditions simultaneously, it creates precedent for the FDA to approve interventions targeting the biology of aging itself. That would unlock billions in pharmaceutical investment.

Observational data is compelling: a 2014 Cardiff University study of 180,000 metformin users found they lived 15% longer than matched non-diabetic controls — people who didn't have diabetes at all. That's either a profound drug effect or a profound confound. TAME is designed to answer which.

Reprogramming: The Nuclear Option

Altos Labs' $3 billion bet is on cellular reprogramming — using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) to partially reverse cells to a more youthful state without fully converting them to stem cells (which would cause tumors). The technique, pioneered by Shinya Yamanaka in 2006, won a Nobel Prize in 2012.

In 2023, Altos demonstrated that partial reprogramming could reverse age-related gene expression signatures by 50–70% in aged mouse tissues. The cells became functionally younger — better at repairing DNA damage, producing normal proteins, and maintaining telomere length — while retaining their tissue identity (a liver cell stayed a liver cell).

The challenge is delivery and dosing. Too little reprogramming does nothing. Too much causes teratomas — tumors made of randomly differentiated tissue. The therapeutic window is narrow, and nobody has a reliable way to hit it in a living human yet. Altos isn't expected to enter human trials before 2028.

The Timeline Debate

Where does this leave longevity escape velocity? The honest answer: probably not this decade, possibly next.

The 3-months-per-year baseline is driven by broad public health improvements — sanitation, antibiotics, cardiovascular care, cancer screening. Reaching 12 months per year requires therapies that don't just treat diseases of aging but reverse the underlying biological damage. We have proof of concept in mice for senolytics, reprogramming, and caloric restriction mimetics. We have exactly zero approved human therapies that target aging itself.

The gap between "works in mice" and "works in humans" is typically 90% attrition. Only 10% of drugs that succeed in preclinical animal models make it through human trials. But the sheer volume of parallel approaches — senolytics, reprogramming, NAD+ restoration, rapamycin analogs, gene therapy, plasma factors — makes it increasingly likely that something will reach clinical practice within 10 years.

Sources & References

1. Life Expectancy — Our World in Data. Best-practice life expectancy has increased by nearly 2.5 years every decade since 1840. Based on Oeppen & Vaupel, "Broken Limits to Life Expectancy," Science, 2002. DOI: 10.1126/science.1069675
2. Altos Labs Launches with $3 Billion for Cellular Rejuvenation — Chemical & Engineering News (ACS), January 2022.
3. Altos Labs Emerges with $3B in Funding — Drug Discovery Trends. Details on Yamanaka factor reprogramming approach.
4. Unity Biotechnology: ASPIRE Phase 2b 36-Week Results for UBX1325 in DME — BioSpace, May 2025. Senolytic targeting Bcl-xL, vision improvement data.
5. TAME: Metformin Anti-Aging Trial — Peter Attia MD. 3,000+ participants aged 65–79, 14 sites, led by Dr. Nir Barzilai, Albert Einstein College of Medicine. Reference: Barzilai N et al., "Metformin as a Tool to Target Aging," Cell Metabolism, 2016. DOI: 10.1016/j.cmet.2016.05.011
6. Can People with Type 2 Diabetes Live Longer Than Those Without? — Cardiff University (ORCA). Currie CJ et al., Diabetes, Obesity and Metabolism, 2014. 180,000 metformin users, 15% longer survival vs matched non-diabetic controls. DOI: 10.1111/dom.12354
7. Diabetes Drug Could Help People Live Longer — ScienceDaily, August 2014. Coverage of the Cardiff metformin longevity study.
8. Dr. James Kirkland: The Senolytics Revolution — Life Extension Magazine. Dasatinib + quercetin senolytic combination; 2015 Mayo Clinic mouse studies showing 36% remaining lifespan extension. Reference: Zhu Y et al., Aging Cell, 2015. DOI: 10.1111/acel.12344
9. Introducing Hevolution Foundation — Hevolution.com. Saudi government-backed, up to $1 billion annual budget for aging research, established by royal decree 2018.
10. Hevolution: The Foundation Pushing Healthy Longevity — Biology Insights. $230M committed to pre-clinical aging biology via Geroscience Research Opportunities Program.
11. Sam Altman-Backed Startup Aims to Add 10 Years to Human Life — Forbes LA. Retro Biosciences, $180M funding, autophagy/plasma factors/reprogramming.
12. NewLimit Secures $130M for Age-Reversing Therapies — Founders Today. Co-founded by Brian Armstrong (Coinbase), epigenetic reprogramming platform.
13. LOY-002 Receives Reasonable Expectation of Effectiveness from FDA — Loyal.com, February 2025. First FDA-backed lifespan drug for large dogs.
14. FDA Accepts Safety Data for Canine Longevity Drug — Veterinary Practice News. LOY-002 regulatory milestone details.
15. NIA Funding Archives — Friends of the National Institute on Aging. NIA/NIH budget figures and AD/ADRD research appropriations.